MNPR Monopar Therapeutics: institutional ownership and insider trading
100 funds reported holding $667M of Monopar Therapeutics in their latest 13F filings; in Q2 2026 funds net sold $789K, with 27 new positions and 14 funds selling out; over the last 12 months insiders bought $105K and sold $4.37M on the open market.
MNPR revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$5.31M
- Quarter ended Mar 31, 2026: revenue $0, net income −$3.89M
- Quarter ended Dec 31, 2025: revenue n/a, net income −$5.20M
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.44M
Famous investors holding MNPR
- Izzy Englander (Millennium Management): $4.66M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $3.43M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.13M, 0.0% of the portfolio
Largest institutional holders of MNPR
- Jupiter Topco LLC — $122M
- JANUS HENDERSON GROUP PLC (JHG) — $72.1M
- RA CAPITAL MANAGEMENT, L.P. — $61.8M
- BlackRock, Inc. (BLK) — $32.3M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $30.0M
- Saturn V Capital Management LP — $28.9M
- Siren, L.L.C. — $25.0M
- ADAR1 Capital Management, LLC — $20.1M
- Polar Capital Holdings Plc — $19.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $19.4M
Recent MNPR insider trades
- Oct 1, 2026: Starr Christopher M sold 8,400 shares ($659K)
- Sep 24, 2026: Robinson Chandler sold 29,056 shares ($2.56M)
- Aug 26, 2026: Tsuchimoto Kim R sold 4,090 shares ($456K)
- Aug 26, 2026: Rioux Patrice sold 1 shares ($111)
5%+ owners
- JANUS HENDERSON GROUP PLC: 19.5% (Schedule 13G/A, filed Nov 14, 2025)
- RA Capital Management, L.P.: 9.9% (Schedule 13G/A, filed Feb 17, 2026)
- AstraZeneca PLC: 7.8% (Schedule 13G/A, filed Feb 6, 2026)